These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36942995)

  • 1. Risk Factors Associated with the Occurrence of Anti-rituximab Antibodies in Membranous Nephropathy.
    Teisseyre M; Brglez V; Cremoni M; Fernandez C; Graça D; Boyer-Suavet S; Benzaken S; Esnault VLM; Seitz-Polski B
    Clin J Am Soc Nephrol; 2023 Jun; 18(6):785-787. PubMed ID: 36942995
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.
    Brenchley PE
    J Am Soc Nephrol; 2015 Oct; 26(10):2308-11. PubMed ID: 25804283
    [No Abstract]   [Full Text] [Related]  

  • 3. [Membranous nephropathy: New insights in therapeutic approach].
    Dahan K
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody.
    Dahan K; Johannet C; Esteve E; Plaisier E; Debiec H; Ronco P
    Kidney Int; 2019 Jan; 95(1):233-234. PubMed ID: 30606419
    [No Abstract]   [Full Text] [Related]  

  • 5. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
    Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
    Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contactin-1-associated membranous nephropathy: complete immunologic and clinical remission with rituximab.
    Plaisier E; Not A; Buob D; Ronco P; Debiec H
    Kidney Int; 2021 Dec; 100(6):1342-1344. PubMed ID: 34802560
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
    Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
    Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy.
    Ruggenenti P; Debiec H; Ruggiero B; Chianca A; Pellé T; Gaspari F; Suardi F; Gagliardini E; Orisio S; Benigni A; Ronco P; Remuzzi G
    J Am Soc Nephrol; 2015 Oct; 26(10):2545-58. PubMed ID: 25804280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.
    Guerry MJ; Vanhille P; Ronco P; Debiec H
    Kidney Int; 2016 Jun; 89(6):1399. PubMed ID: 27181779
    [No Abstract]   [Full Text] [Related]  

  • 10. Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.
    van de Logt AE; Dahan K; Rousseau A; van der Molen R; Debiec H; Ronco P; Wetzels J
    Kidney Int; 2018 Apr; 93(4):1016-1017. PubMed ID: 29571438
    [No Abstract]   [Full Text] [Related]  

  • 11. Rituximab bioavailability in primary membranous nephropathy.
    Boyer-Suavet S; Andreani M; Cremoni M; Brglez V; Benzaken S; Bernard G; Nachman P; Esnault V; Seitz-Polski B
    Nephrol Dial Transplant; 2019 Aug; 34(8):1423-1425. PubMed ID: 30929012
    [No Abstract]   [Full Text] [Related]  

  • 12. Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy.
    Teisseyre M; Cremoni M; Boyer-Suavet S; Crepin T; Benzaken S; Zorzi K; Esnault V; Brglez V; Seitz-Polski B
    Front Immunol; 2021; 12():738788. PubMed ID: 34721403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
    Lu W; Gong S; Li J; Luo H; Wang Y
    Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Dose Rituximab and Early Remission in PLA2R1-Related Membranous Nephropathy.
    Seitz-Polski B; Dahan K; Debiec H; Rousseau A; Andreani M; Zaghrini C; Ticchioni M; Rosenthal A; Benzaken S; Bernard G; Lambeau G; Ronco P; Esnault VLM
    Clin J Am Soc Nephrol; 2019 Aug; 14(8):1173-1182. PubMed ID: 31340979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy.
    Beck LH; Fervenza FC; Beck DM; Bonegio RG; Malik FA; Erickson SB; Cosio FG; Cattran DC; Salant DJ
    J Am Soc Nephrol; 2011 Aug; 22(8):1543-50. PubMed ID: 21784898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent Membranous Nephropathy After Kidney Transplantation Associated With Phospholipase A2 Receptor and Successfully Treated With Rituximab: A Case Report.
    Ishiwatari A; Wakai S; Shirakawa H; Honda K
    Transplant Proc; 2018 Oct; 50(8):2565-2568. PubMed ID: 30316399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monthly mini-dose rituximab for primary anti-PLA2R-positive membranous nephropathy: a personalized approach.
    Wang S; Deng Z; Wang Y; Bao W; Zhou S; Cui Z; Zheng D
    BMC Nephrol; 2023 May; 24(1):146. PubMed ID: 37237260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy.
    Hoxha E; Harendza S; Pinnschmidt H; Panzer U; Stahl RA
    Clin J Am Soc Nephrol; 2014 Nov; 9(11):1883-90. PubMed ID: 25267554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Beneficial Role Of Anti-Phospholipase A2 Receptor Auto-Antibodies And Rituximab In The Management Of Recurrent Primary Membranous Nephropathy After Kidney Transplantation.
    Anjum N; Nabi Z
    J Ayub Med Coll Abbottabad; 2021; 33(2):315-318. PubMed ID: 34137554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up.
    Zhou XJ; Zhou FD; Wang SX; Zhao MH
    Medicine (Baltimore); 2018 Jun; 97(25):e11184. PubMed ID: 29924035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.